We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+7.26%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$263M
AUM Growth
+$1.92M
Cap. Flow
-$11.8M
Cap. Flow %
-4.49%
Top 10 Hldgs %
51.63%
Holding
68
New
8
Increased
22
Reduced
13
Closed
8

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$5.37M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$3.68M
3
AERI
Aerie Pharmaceuticals
AERI
+$3.67M
4
RDUS
Radius Health, Inc.
RDUS
+$3.63M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$2.63M

Top Sells

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$7.83M
2
SUPN icon
Supernus Pharmaceuticals
SUPN
+$6.37M
3
INCY icon
Incyte
INCY
+$6.36M
4
SHPG
Shire pic
SHPG
+$6.2M
5
BMY icon
Bristol-Myers Squibb
BMY
+$5.33M

Sector Composition

Rank Sector Weight
1 Healthcare 98.93%
2 Miscellaneous 1.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
26
DELISTED
Seagen Inc. Common Stock
SGEN
$3.36M 1.28%
65,000
– –
AKAO
27
DELISTED
Achaogen Inc
AKAO
$3.36M 1.28%
154,538
-125,500
-45% -$2.87M
CLVS
28
DELISTED
Clovis Oncology, Inc.
CLVS
$3.28M 1.24%
35,000
+15,000
+75% +$918K
ADMS
29
DELISTED
Adamas Pharmaceuticals
ADMS
$3.24M 1.23%
185,234
– –
ARRY
30
DELISTED
Array Biopharma Inc
ARRY
$2.68M 1.02%
320,744
+243,244
+314% +$1.99M
HALO icon
31
Halozyme
HALO
$12.1B
$2.62M 1%
204,633
-153,367
-43% -$2.05M
IONS icon
32
Ionis Pharmaceuticals
IONS
$10.4B
$2.62M 1%
51,500
– –
ILMN icon
33
Illumina
ILMN
$34.4B
$2.37M 0.9%
14,023
-45,232
-76% -$7.83M
KITE
34
DELISTED
Kite Pharma, Inc.
KITE
$2.29M 0.87%
22,100
-33,400
-60% -$2.73M
KALV
35
DELISTED
KalVista Pharmaceuticals
KALV
$2.28M 0.86%
322,436
– –
PRTA icon
36
Prothena Corp
PRTA
$467M
$2.27M 0.86%
42,000
– –
SRPT icon
37
Sarepta Therapeutics
SRPT
$2.28B
$2.06M 0.78%
+61,000
New +$1.99M
HZNP
38
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$2M 0.76%
169,000
+84,000
+99% +$1.04M
AGIO icon
39
Agios Pharmaceuticals
AGIO
$2.05B
$1.9M 0.72%
37,000
+17,000
+85% +$869K
FOMX
40
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$1.67M 0.63%
358,975
+161,137
+81% +$719K
VCYT icon
41
Veracyte
VCYT
$3.64B
$1.41M 0.54%
170,000
– –
PRTK
42
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$1.4M 0.53%
+58,000
New +$1.28M
SAGE
43
DELISTED
Sage Therapeutics
SAGE
$1.35M 0.51%
16,996
– –
ICPT
44
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1.35M 0.51%
11,155
– –
FPRX
45
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$1.24M 0.47%
+41,000
New +$1.28M
IRWD icon
46
Ironwood Pharmaceuticals
IRWD
$701M
$1.11M 0.42%
70,446
– –
LGND icon
47
Ligand Pharmaceuticals
LGND
$5.67B
$1.09M 0.42%
14,427
– –
VNDA icon
48
Vanda Pharmaceuticals
VNDA
$329M
$1.02M 0.39%
62,905
-72,912
-54% -$1.05M
MRUS
49
DELISTED
Merus
MRUS
$966K 0.37%
+60,946
New +$1.16M
MGNX icon
50
MacroGenics
MGNX
$260M
$945K 0.36%
54,000
– –
1
2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q2 2017 Portfolio in Review

As of Q2 2017, International Biotechnology Trust held 68 positions worth $263M, up 0.73% from $261M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

International Biotechnology Trust withdrew a net $11.8M in Q2 2017, closing 8 positions and reducing 13 holdings. Its most notable exit was Bristol-Myers Squibb, an estimated $5.33M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, International Biotechnology Trust opened a new position in Viatris worth $5.43M.

  • International Biotechnology Trust's largest Q2 2017 buy was Viatris: 140,000 shares worth $5.43M.
  • International Biotechnology Trust added most to BioMarin Pharmaceuticals in Q2 2017, an estimated $3.68M increase.
  • International Biotechnology Trust's biggest Q2 2017 reduction was Illumina, cutting an estimated $7.83M.
  • International Biotechnology Trust fully exited Bristol-Myers Squibb in Q2 2017, selling an estimated $5.33M.
  • International Biotechnology Trust's ten largest holdings make up 52% of its $263M portfolio in Q2 2017.
  • International Biotechnology Trust opened 8 new positions and closed 8 in Q2 2017.
  • International Biotechnology Trust's portfolio value rose 0.73% quarter-over-quarter to $263M.

Based on International Biotechnology Trust's 13F filing for Q2 2017, filed 2 Mar 2018.